(Sharecast News) – The Sunday Times’s Lucy Tobin told readers that shares of Futura Medical were worth a punt, even if there were no guarantees of a happy ending.
Although the company had just 14 staff and directors, it had a new product that worked, Eroxon, a gel for those suffering from erectile dysfunction, which did not require a prescription in order to be sold.
Given that the market for ED was expected to surpass $6bn in value by 2032, the business’s future looked appealing.
And unlike rival products Viagra and Cialis, both of which required a prescription, Eroxon took just 10 minutes to work, not half an hour.
The company was expecting approval for Eroxon in Saudi Arabia in September and was working on having a US partner for commercialisation which would likely a surge in the share price.
“There are no guarantees of a happy ending, but it’s a worthy punt. Buy.”
The Financial Mail on Sunday’s told readers to ‘buy’ shares of Serco, although it conceded that risks were not absent.
The outsourcer was well-placed to benefit form government outlays on immigration and defence in many regions of the world, the tipster argued.
On the flip-side, there were multiple potential risks.
For starters, making up the loss of Covid-related work “wasn’t always easy”.
Furthermore, the possibility existed that it might lose the Australian immigration contract that was up for renewal in 2023.
Serco also had a tendency to work in “high-profile” and “controversial” areas, including on immigration which in the past had led to scandal and had an extremely negative impact on its share prices.
“There’s no suggestion that the current management is likely to lead the company into any problems like this though, since former chief executive Rupert Soames is credited with shaking out any problems at the business, leaving it in stronger shape.
“At 156p, the shares are a buy.”
